NCT04352985No Longer Available不适用
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
Spectral Diagnostics (US) Inc.3 个研究点 分布在 1 个国家开始时间: 2020年4月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 3
研究概览
简要总结
Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
详细描述
This is a compassionate use protocol for a population of patients with an immediately life-threatening condition, for whom no comparable alternative therapy options are available. The PMX cartridge will be utilized to treat critically ill patients with septic shock who also have COVID 19 virus. The objective will be to observe the efficacy of the PMX cartridge with a focus on safety of use in this population.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of age
- •Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours
- •Norepinephrine > 0.05mcg/kg/min
- •Dopamine > 10 mcg/kg/min
- •Phenylephrine > 0.4 mcg/kg/min
- •Epinephrine > 0.05 mcg/kg/min
- •Vasopressin > 0.03 units/min
- •Vasopressin (any dose) in combination with another vasopressor listed above
- •The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility
- •Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration
- •The subject must have a screening multi-organ dysfunction score (MODS) >9
- •Endotoxin Activity Assay between ≥ 0.60 to <0.90 EA units
- •Evidence of at least 1 of the following criteria for new onset organ dysfunction that is considered to be due to the acute illness:
- •Requirement for positive pressure ventilation via an endotracheal tube or tracheostomy tube
- •Thrombocytopenia defined as acute onset of platelet count <150,000µ/L or a reduction of 50% from prior known levels
- •Acute oliguria defined as urine output <0.5mL/kg/hr for at least 6 hours despite adequate fluid resuscitation
- •Positive COVID 19 diagnosis
排除标准
- •Inability to obtain an informed consent from the subject, family member or an authorized surrogate
- •Lack of commitment for full medical support
- •Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation
- •Subject has end-stage renal disease and requires chronic dialysis
- •There is clinical support for non-septic shock such as:
- •Acute pulmonary embolus
- •Transfusion reaction
- •Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction < 35%)
- •Subject has had chest compressions as part of CPR during this hospitalization without immediate return to communicative state
- •Subject has had an acute myocardial infarction (AMI) within the past 4 weeks
- •Subject has uncontrolled hemorrhage (acute blood loss requiring > 3 UPC in the past 24 hours)
- •Major trauma within 36 hours of screening
- •Subject has severe granulocytopenia (leukocyte count less than 500 cells/mm3) or severe thrombocytopenia (platelet count less than 30,000 cells/mm3)
- •HIV infection in association with a last known or suspected CD4 count of <50/mm3
- •Subject's baseline state is non-communicative
- •Subject has sustained extensive third-degree burns within the past 7 days
- •Body weight < 35 kg (77 pounds)
- •Known hypersensitivity to Polymyxin B
- •Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia (H.I.T.)
- •Subject is currently enrolled in an investigational drug or device trial
- •Subject has been previously enrolled in the current trial
- •Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end-stage chronic illness (eg. lack of source control and bowel necrosis) with no reasonable expectation of survival to hospital discharge
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic ShockSeptic ShockEndotoxemiaNCT01046669Spectral Diagnostics (US) Inc.450
Temporarily Not Available
不适用
Open-label Evaluation of Polymyxin B Hemoperfusion for Septic ShockSeptic ShockEndotoxemiaNCT02825329Spectral Diagnostics (US) Inc.
终止
不适用
Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract InfectionSepsisNCT02871024National Taiwan University Hospital1
Unknown
不适用
Safety and Efficacy of Heparin Dosing Score Protocol for Polymyxin-B HemoperfusionPolymyxin B HemoperfusionSeptic ShockNCT03177330National Taiwan University Hospital30
已完成
不适用
The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe SepsisSevere SepsisNCT02413541Chulalongkorn University90